Compare MYSZ & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MYSZ | APVO |
|---|---|---|
| Founded | 1999 | 2016 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5M | 8.3M |
| IPO Year | 2017 | 2023 |
| Metric | MYSZ | APVO |
|---|---|---|
| Price | $0.42 | $4.78 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 71.9K | 26.2K |
| Earning Date | 04-15-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.40 | 0.13 |
| EPS | ★ N/A | N/A |
| Revenue | $142,000.00 | ★ $3,114,000.00 |
| Revenue This Year | $41.64 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 125.40 | N/A |
| 52 Week Low | $0.46 | $0.50 |
| 52 Week High | $1.65 | $13.11 |
| Indicator | MYSZ | APVO |
|---|---|---|
| Relative Strength Index (RSI) | 33.26 | 48.67 |
| Support Level | N/A | $4.29 |
| Resistance Level | $0.67 | $5.59 |
| Average True Range (ATR) | 0.06 | 0.31 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 4.42 | 40.19 |
My Size Inc is a fashion technology company operating an integrated portfolio of businesses designed to address the pressing challenges facing fashion brands and retailers today - size and fit accuracy, excess inventory management, circular economy solutions, and international market distribution. The company, through its subsidaries provide end-to-end support across the fashion value chain; delivers AI-driven size and fit solutions for fashion e-commerce companies. The firm has the following four segments: (i) Fashion e-commerce platform, (ii) SaaS solutions, (iii) resale platform for apparel, and (iv) wholesaling of footwear. The company generates the majority of its revenue from the fashion e-commerce platform segment.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.